215 related articles for article (PubMed ID: 24548720)
1. The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate.
Grasmeijer F; de Boer AH
Int J Pharm; 2014 Apr; 465(1-2):165-8. PubMed ID: 24548720
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the fundamental understanding of adhesive mixtures for inhalation.
Grasmeijer F; Grasmeijer N; Hagedoorn P; Frijlink HW; Haaije de Boer A
Curr Pharm Des; 2015; 21(40):5900-14. PubMed ID: 26446471
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary drug delivery by powder aerosols.
Yang MY; Chan JG; Chan HK
J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
[TBL] [Abstract][Full Text] [Related]
4. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
Lin YW; Wong J; Qu L; Chan HK; Zhou QT
Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
[TBL] [Abstract][Full Text] [Related]
5. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
Rogueda PG; Traini D
Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
[TBL] [Abstract][Full Text] [Related]
6. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
8. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
9. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics.
Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
J Pharm Sci; 2007 May; 96(5):1282-301. PubMed ID: 17455324
[TBL] [Abstract][Full Text] [Related]
10. The role of particle properties in pharmaceutical powder inhalation formulations.
Chew NY; Chan HK
J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
[TBL] [Abstract][Full Text] [Related]
11. Multi-scale modelling of powder dispersion in a carrier-based inhalation system.
Tong Z; Kamiya H; Yu A; Chan HK; Yang R
Pharm Res; 2015 Jun; 32(6):2086-96. PubMed ID: 25511919
[TBL] [Abstract][Full Text] [Related]
12. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
Tong Z; Yu A; Chan HK; Yang R
Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
[TBL] [Abstract][Full Text] [Related]
13. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems.
Wong W; Fletcher DF; Traini D; Chan HK; Crapper J; Young PM
J Pharm Sci; 2011 Jul; 100(7):2744-54. PubMed ID: 21360707
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of the DP-4M PennCentury insufflator.
Hoppentocht M; Hoste C; Hagedoorn P; Frijlink HW; de Boer AH
Eur J Pharm Biopharm; 2014 Sep; 88(1):153-9. PubMed ID: 24993307
[TBL] [Abstract][Full Text] [Related]
15. Orally inhaled drug performance testing for product development, registration, and quality control.
Lastow O; Svensson M
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):401-7. PubMed ID: 25237712
[TBL] [Abstract][Full Text] [Related]
16. Development of dry powder inhalers.
Chougule MB; Padhi BK; Jinturkar KA; Misra A
Recent Pat Drug Deliv Formul; 2007; 1(1):11-21. PubMed ID: 19075871
[TBL] [Abstract][Full Text] [Related]
17. How can we bring high drug doses to the lung?
Claus S; Weiler C; Schiewe J; Friess W
Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
[TBL] [Abstract][Full Text] [Related]
18. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
Cordts E; Steckel H
Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789
[TBL] [Abstract][Full Text] [Related]
19. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
20. Dry powder inhalers for pulmonary drug delivery.
Frijlink HW; De Boer AH
Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
